PMID- 12195360
OWN - NLM
STAT- MEDLINE
DCOM- 20020924
LR  - 20131121
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 186
IP  - 5
DP  - 2002 Sep 1
TI  - Eradication of human immunodeficiency virus type 1-infected cells by a 
      combination of antimetabolic cytotoxic chemotherapy and antiviral chemotherapy in 
      vitro: a pilot study.
PG  - 706-9
AB  - Although highly active antiretroviral therapy against human immunodeficiency 
      virus (HIV) type 1 reduces the mortality of persons with acquired 
      immunodeficiency syndrome, it does not eliminate HIV reservoirs. In this study, 
      which used a 6-thioguanine (6-TG) resistant clone (4C6) of the MT-2 cell line as 
      a model, the combination of 6-TG with both reverse-transcriptase (RT) inhibitor 
      and protease inhibitor or 6-TG with a protease inhibitor alone completely 
      eradicated HIV-1-carrying cells from the culture and protected uninfected 4C6 
      cells from HIV-1 infection. The combination of 6-TG and a RT inhibitor, 
      azidothymidine, provided partial protection. Protection was extended to human 
      peripheral blood mononuclear cells. These results suggest that adding a cytotoxic 
      drug in combination antiviral chemotherapy may reduce the establishment of virus 
      reservoirs and prevent virus spread. The clinical value of this and similar 
      strategies should be further evaluated in HIV-infected patients.
FAU - Yang, Quan-en
AU  - Yang QE
AD  - Laboratory of Antiviral Drug Mechanisms, Science Applications International 
      Corporation-Frederick, National Cancer Institute, Frederick, Maryland 21702, USA. 
      yangq@dtpax2.ncifcrf.gov
FAU - Li, Kun-gui
AU  - Li KG
FAU - Mikovits, Judy A
AU  - Mikovits JA
LA  - eng
GR  - N01-CO-56000/CO/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20020801
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (HIV Core Protein p24)
RN  - 0 (HIV Protease Inhibitors)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - FTK8U1GZNX (Thioguanine)
SB  - IM
MH  - Cells, Cultured
MH  - Drug Therapy, Combination
MH  - HIV Core Protein p24/biosynthesis
MH  - HIV Infections/*drug therapy
MH  - HIV Protease Inhibitors/*pharmacology
MH  - HIV-1/*drug effects
MH  - Humans
MH  - Pilot Projects
MH  - Reverse Transcriptase Inhibitors/*pharmacology
MH  - Thioguanine/*pharmacology
EDAT- 2002/08/27 10:00
MHDA- 2002/09/25 06:00
CRDT- 2002/08/27 10:00
PHST- 2001/12/19 00:00 [received]
PHST- 2002/04/18 00:00 [revised]
PHST- 2002/08/27 10:00 [pubmed]
PHST- 2002/09/25 06:00 [medline]
PHST- 2002/08/27 10:00 [entrez]
AID - JID011497 [pii]
AID - 10.1086/342049 [doi]
PST - ppublish
SO  - J Infect Dis. 2002 Sep 1;186(5):706-9. doi: 10.1086/342049. Epub 2002 Aug 1.